Targeting fibronectins of glioma extracellular matrix by CLT1 peptide-conjugated nanoparticles

Biomaterials

Volumn 35, Issue 13, 2014, Pages 4088-4098

  Zhang, Bo ^a   Shen, Shun ^b   Liao, Ziwei ^b   Shi, Wei ^a   Wang, Yu ^b   Zhao, Jingjing ^b   Hu, Yue ^c   Yang, Jiarong ^c   Chen, Jun ^b   Mei, Heng ^a   Hu, Yu ^a   Pang, Zhiqing ^b   Jiang, Xinguo ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b FUDAN UNIVERSITY   (China)

^c JIAMUSI UNIVERSITY   (China)

Author keywords

Extracellular matrix; Fibronectin; Glioma; Nanoparticles; Retention; Targeting

Indexed keywords

EXTRACELLULAR MATRICES; FIBRONECTIN; GLIOMA; RETENTION; TARGETING;

CELL DEATH; DRUG DELIVERY; GLYCOPROTEINS; HISTOLOGY; NANOPARTICLES; PEPTIDES;

TUMORS;

CLT1 PEPTIDE; COPOLYMER; FIBRONECTIN; NANOCARRIER; PACLITAXEL; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; CYCLO(CYSTEINYL-GLYCYL-LEUCYL-ISOLEUCYL-ISOLEUCYL-GLUTAMINYL-LYSYL-ASPARAGINYL-GLUTAMYL-CYSTEINYL); CYCLOPEPTIDE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; EX VIVO STUDY; EXTRACELLULAR MATRIX; FROZEN SECTION; GLIOMA; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN TARGETING; SOLID TUMOR; SURVIVAL TIME; TISSUE SLICE; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; MALE; RAT; TUMOR CELL LINE;

MUS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; EXTRACELLULAR MATRIX; FIBRONECTINS; GLIOMA; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PEPTIDES, CYCLIC; RATS;

EID: 84896716175     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.046     Document Type: Article

References (58)

1. Behin A., Hoang-Xuan K., Carpentier A.F., Delattre J.Y. Primary brain tumours in adults. Lancet 2003, 361(9354):323-331.
2. DeAngelis L.M. Brain tumors. NEngl J Med 2001, 344(2):114-123.
3. Wrensch M., Minn Y., Chew T., Bondy M., Berger M.S. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002, 4(4):278-299.
4. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2):97-109.
5. Roger M., Clavreul A., Venier-Julienne M.C., Passirani C., Montero-Menei C., Menei P. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 2010, 32(8):2106-2116.
6. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338(6109):903-910.
7. Gu G., Xia H., Hu Q., Liu Z., Jiang M., Kang T., et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials 2012, 34(1):196-208.
8. Xin H., Sha X., Jiang X., Zhang W., Chen L., Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 2012, 33(32):8167-8176.
9. Hu Q., Gao X., Gu G., Kang T., Tu Y., Liu Z., et al. Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. Biomaterials 2013, 34(22):5640-5650.
10. Zhang B., Sun X., Mei H., Wang Y., Liao Z., Chen J., et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials 2013, 34(36):9171-9182.
11. Zhan C., Li B., Hu L., Wei X., Feng L., Fu W., et al. Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. Angew Chem Int Ed Engl 2011, 50(24):5482-5485.
12. Ying X., Wen H., Lu W.L., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. JControl Release 2009, 141(2):183-192.
13. Jones T.S., Holland E.C. Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene 2011, 31(16):1995-2006.
14. Navis A.C., Bourgonje A., Wesseling P., Wright A., Hendriks W., Verrijp K., et al. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PLoS One 2013, 8(3):e58262.
15. Bae Y.H., Park K. Targeted drug delivery to tumors: myths, reality and possibility. JControl Release 2011, 153(3):198-205.
16. Boult J., Roberts K., Brookes M.J., Hughes S., Bury J.P., Cross S.S., et al. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res 2008, 14(2):379-387.
17. Chirasani S.R., Markovic D.S., Synowitz M., Eichler S.A., Wisniewski P., Kaminska B., et al. Transferrin-receptor-mediated iron accumulation controls proliferation and glutamate release in glioma cells. JMol Med (Berl) 2009, 87(2):153-167.
18. Magro G., Cataldo I., Amico P., Torrisi A., Vecchio G.M., Parenti R., et al. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid 2011, 21(3):267-277.
19. Ulrich T.A., de Juan Pardo E.M., Kumar S. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 2009, 69(10):4167-4174.
20. Zamecnik J. The extracellular space and matrix of gliomas. Acta Neuropathol 2005, 110(5):435-442.
21. Kaspar M., Zardi L., Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006, 118(6):1331-1339.
22. Zhou R., Zhou H., Xiong B., He Y., Yeung E.S. Pericellular matrix enhances retention and cellular uptake of nanoparticles. JAm Chem Soc 2012, 134(32):13404-13409.
23. Dvorak H.F., Senger D.R., Dvorak A.M., Harvey V.S., McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985, 227(4690):1059-1061.
24. Ohnishi T., Hiraga S., Izumoto S., Matsumura H., Kanemura Y., Arita N., et al. Role of fibronectin-stimulated tumor cell migration in glioma invasion invivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin Exp Metastasis 1998, 16(8):729-741.
25. Santimaria M., Moscatelli G., Viale G.L., Giovannoni L., Neri G., Viti F., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003, 9(2):571-579.
26. Menrad A., Menssen H.D. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005, 9(3):491-500.
27. Nam J.M., Onodera Y., Bissell M.J., Park C.C. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res 2010, 70(13):5238-5248.
28. Pilch J., Brown D.M., Komatsu M., Jarvinen T.A., Yang M., Peters D., et al. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci U S A 2006, 103(8):2800-2804.
29. Tan M., Wu X., Jeong E.K., Chen Q., Lu Z.R. Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules 2010, 11(3):754-761.
30. Tan M., Wu X., Jeong E.K., Chen Q., Parker D.L., Lu Z.R. An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix. Mol Pharm 2010, 7(4):936-943.
31. Dong Y., Feng S.S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25(14):2843-2849.
32. Wen Z., Yan Z., Hu K., Pang Z., Cheng X., Guo L., et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. JControl Release 2011, 151(2):131-138.
33. Gunther W., Pawlak E., Damasceno R., Arnold H., Terzis A.J. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer 2003, 88(3):463-469.
34. Sauer S., Erba P.A., Petrini M., Menrad A., Giovannoni L., Grana C., et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113(10):2265-2274.
35. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60(15):1615-1626.
36. Peng L., Liu R., Marik J., Wang X., Takada Y., Lam K.S. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for invivo tumor imaging. Nat Chem Biol 2006, 2(7):381-389.
37. Merisko-Liversidge E.M., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008, 36(1):43-48.
38. Nicolas J., Mura S., Brambilla D., Mackiewicz N., Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev 2012, 42(3):1147-1235.
39. Mariani G., Lasku A., Pau A., Villa G., Motta C., Calcagno G., et al. Apilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. Cancer 1997, 80(Suppl.12):2484-2489.
40. Mariani G., Lasku A., Balza E., Gaggero B., Motta C., Di Luca L., et al. Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer 1997, 80(Suppl.12):2378-2384.
41. Shi W., Mei H., Deng J., Chen C., Wang H., Guo T., et al. Atissue factor targeted nanomedical system for thrombi-specific drug delivery. Biomaterials 2012, 33(30):7643-7654.
42. Mei H., Shi W., Pang Z., Wang H., Lu W., Jiang X., et al. EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery. Biomaterials 2010, 31(21):5619-5626.
43. Graf N., Bielenberg D.R., Kolishetti N., Muus C., Banyard J., Farokhzad O.C., et al. alpha(V)beta(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano 2012, 6(5):4530-4539.
44. Glimelius B., Norling B., Nederman T., Carlsson J. Extracellular matrices in multicellular spheroids of human glioma origin: increased incorporation of proteoglycans and fibronectin as compared to monolayer cultures. APMIS 1988, 96(5):433-444.
45. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4(6):437-447.
46. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427(6976):695.
47. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., Farokhzad O.C., et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013, 73(8):2412-2417.
48. Huo S., Ma H., Huang K., Liu J., Wei T., Jin S., et al. Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Res 2012, 73(1):319-330.
49. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. JClin Oncol 2013, 31(17):2205-2218.
50. Mehta G., Hsiao A.Y., Ingram M., Luker G.D., Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. JControl Release 2012, 164(2):192-204.
51. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32(31):8010-8020.
52. Juweid M., Neumann R., Paik C., Perez-Bacete M.J., Sato J., van Osdol W., et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992, 52(19):5144-5153.
53. Goodman T.T., Chen J., Matveev K., Pun S.H. Spatio-temporal modeling of nanoparticle delivery to multicellular tumor spheroids. Biotechnol Bioeng 2008, 101(2):388-399.
54. Lee H., Fonge H., Hoang B., Reilly R.M., Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm 2010, 7(4):1195-1208.
55. Saga T., Neumann R.D., Heya T., Sato J., Kinuya S., Le N., et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U S A 1995, 92(19):8999-9003.
56. Vlashi E., Sturgis J.E., Thomas M., Low P.S. Real time, noninvasive imaging and quantitation of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors. Mol Pharm 2009, 6(6):1868-1875.
57. Knowles L.M., Malik G., Hood B.L., Conrads T.P., Pilch J. CLT1 targets angiogenic endothelium through CLIC1 and fibronectin. Angiogenesis 2011, 15(1):115-129.
58. Knowles L.M., Zewe J., Malik G., Parwani A.V., Gingrich J.R., Pilch J. CLT1 targets bladder cancer through integrin alpha5beta1 and CLIC3. Mol Cancer Res 2012, 11(2):194-203.